Anti-human RANKL antibody, humanized antibody of the same, and pharmaceutical composition and use thereof
An anti-human RANKL antibody, a humanized antibody for the anti-human RANKL antibody, a pharmaceutical composition and a use thereof are provided. The anti-human RANKL antibody is capable of bonding specifically with an amino acid sequence of SEQ ID NO.1, a heavy chain of the anti-human RANKL antibody includes a variable region in one of amino acid sequences of SEQ ID NO.2-9, and a light chain of the anti-human RANKL antibody includes a variable region in one of amino acid sequences of SEQ ID NO.10-17. The humanized antibody is capable of bonding specifically with human RANKL, a variable region in a heavy chain of the humanized antibody is selected from amino acid sequences of SEQ ID NO.6, NO.23, NO.25, NO.27 or NO.29, and a variable region in a light chain of the humanized antibody is selected from amino acid sequences of SEQ ID NO.14, NO.31, NO.33, NO.35, NO.37 or NO.39.
1. An anti-human RANKL monoclonal antibody, wherein the anti-human RANKL monoclonal antibody comprises a heavy chain and a light chain, wherein a) the heavy chain comprises a variable region, the sequence of which is one of amino acid sequences SEQ ID NO.2-9, and b) the light chain comprises a variable region, the sequence of which is one of amino acid sequences SEQ ID NO.10-17; and the antibody binds with RANKL to block an interaction between RANK and RANKL, or a human RANKL binding fragment of such antibody.
2. The anti-human RANKL monoclonal antibody according to claim 1 , wherein the antibody comprises a heavy chain and a light chain, wherein the heavy chain comprises a variable region with the amino acid sequence of SEQ ID NO. 2, and the light chain comprises a variable region with the amino acid sequence of SEQ ID NO.10; or, the heavy chain comprises a variable region with the amino acid sequence of SEQ ID NO. 3, and the light chain comprises a variable region with the amino acid sequence of SEQ ID NO.11; or, the heavy chain comprises a variable region with the amino acid sequence of SEQ ID NO. 4, and the light chain comprises a variable region with the amino acid sequence of SEQ ID NO.12; or, the heavy chain comprises a variable region with the amino acid sequence of SEQ ID NO. 5, and the light chain comprises a variable region with the amino acid sequence of SEQ ID NO.13; or, the heavy chain comprises a variable region with the amino acid sequence of SEQ ID NO. 6, and the light chain comprises a variable region with the amino acid sequence of SEQ ID NO.14; or, the heavy chain comprises a variable region with the amino acid sequence of SEQ ID NO. 7, and the light chain comprises a variable region with the amino acid sequence of SEQ ID NO.15; or, the heavy chain comprises a variable region with the amino acid sequence of SEQ ID NO. 8, and the light chain comprises a variable region with the amino acid sequence of SEQ ID NO.16; or, the heavy chain comprises a variable region with the amino acid sequence of SEQ ID NO. 9, and the light chain comprises a variable region with the amino acid sequence of SEQ ID NO.17.
3. The anti-human RANKL monoclonal antibody according to claim 1 , wherein the antibody comprises a heavy chain and a light chain, wherein the heavy chain comprises a variable region with the amino acid sequence of SEQ ID NO. 6, and the light chain comprises a variable region with the amino acid sequence of SEQ ID NO.14.
4. The anti-human RANKL monoclonal antibody according to claim 1 , wherein the anti-human RANKL monoclonal antibody is a single-chain antibody, a humanized antibody, or a murine monoclonal antibody obtained by means of hybridoma technique.
5. A humanized anti-human RANKL monoclonal antibody according to claim 1 , wherein the humanized monoclonal antibody is capable of binding specifically with human RANKL and comprises a variable region in a heavy chain of the humanized monoclonal antibody with an amino acid sequence selected from amino acid sequences SEQ ID NO.6, NO.23, NO.25, NO.27 or NO.29, and a variable region in a light chain of the humanized monoclonal antibody with an amino acid sequence selected from amino acid sequences SEQ ID NO.14, NO.31, NO.33, NO.35, NO.37 or NO.39.
6. The humanized monoclonal antibody according to claim 5 , wherein the variable region in the heavy chain comprises amino acids with the sequence of SEQ ID NO.6, and the variable region in the light chain comprises amino acids with the sequence of SEQ ID NO.14; or
the variable region in the heavy chain comprises amino acids with the sequence of SEQ ID NO.23, and the variable region in the light chain comprises amino acids with the sequence of SEQ ID NO. 31; or
the variable region in the heavy chain comprises amino acids with the sequence of SEQ ID NO.23, and the variable region in the light chain comprises amino acids with the sequence of SEQ ID NO.35; or
the variable region in the heavy chain comprises amino acids with the sequence of SEQ ID NO.23, and the variable region in the light chain comprises amino acids with the sequence of SEQ ID NO.33; or
the variable region in the heavy chain comprises amino acids with the sequence of SEQ ID NO.23, and the variable region in the light chain comprises amino acids with the sequence of SEQ ID NO.37; or
the variable region in the heavy chain comprises amino acids with the sequence of SEQ ID NO.27, and the variable region in the light chain comprises amino acids with the sequence of SEQ ID NO.31; or
the variable region in the heavy chain comprises amino acids with the sequence of SEQ ID NO.27, and the variable region in the light chain comprises amino acids with the sequence of SEQ ID NO.35; or
the variable region in the heavy chain comprises amino acids with the sequence of SEQ ID NO.27, and the variable region in the light chain comprises amino acids with the sequence of SEQ ID NO.33; or
the variable region in the heavy chain comprises amino acids with the sequence of SEQ ID NO.27, and the variable region in the light chain comprises amino acids with the sequence of SEQ ID NO.37; or
the variable region in the heavy chain comprises amino acids with the sequence of SEQ ID NO.25, and the variable region in the light chain comprises amino acids with the sequence of SEQ ID NO.31; or
the variable region in the heavy chain comprises amino acids with the sequence of SEQ ID NO.25, and the variable region in the light chain comprises amino acids with the sequence of SEQ ID NO.35; or
the variable region in the heavy chain comprises amino acids with the sequence of SEQ ID NO.25, and the variable region in the light chain comprises amino acids with the sequence of SEQ ID NO.33; or
the variable region in the heavy chain comprises amino acids with the sequence of SEQ ID NO.25, and the variable region in the light chain comprises amino acids with the sequence of SEQ ID NO.37; or
the variable region in the heavy chain comprises amino acids with the sequence of SEQ ID NO.29, and the variable region in the light chain comprises amino acids with the sequence of SEQ ID NO.39; or
the variable region in the heavy chain comprises amino acids with the sequence of SEQ ID NO.29, and the variable region in the light chain comprises amino acids with the sequence of SEQ ID NO.31.
7. The humanized monoclonal antibody according to claim 5 , wherein a constant region in the heavy chain of the humanized monoclonal antibody is human IgG2, and a constant region in the light chain of the humanized monoclonal antibody is human Kappa; or, a constant region in the heavy chain of the humanized monoclonal antibody is amino acids with the sequence of SEQ ID NO.41, and a constant region in the light chain of the humanized monoclonal antibody is amino acids with the sequence of SEQ ID NO.43.
8. The humanized monoclonal antibody according to claim 5 , wherein the humanized monoclonal antibody is an antigen binding segment selected from Fab, Fab′ or F(ab′) 2 .
9. The humanized monoclonal antibody according to claim 7 , wherein the heavy chain of the humanized monoclonal antibody has an amino acid sequence selected from an amino acid sequence of one of SEQ ID NOs.: 46-50, or the light chain of the humanized monoclonal antibody is has an amino acid sequence selected from an amino acid sequence of one of SEQ ID NOs.: 51-56.
10. The humanized monoclonal antibody according to claim 9 , wherein the complete heavy chain of the humanized monoclonal antibody comprises the amino acid sequence of SEQ ID NO. 46, the complete light chain of the humanized monoclonal antibody comprises the amino acid sequence of SEQ ID NO.51; or, the complete heavy chain of the humanized monoclonal antibody comprises the amino acid sequence of SEQ ID NO.47, the complete light chain of the humanized monoclonal antibody comprises the amino acid sequence of SEQ ID NO.52, NO.53, NO.54 or NO.55; or, the complete heavy chain of the humanized monoclonal antibody comprises the amino acid sequence of SEQ ID NO. 48, the complete light chain of the humanized monoclonal antibody comprises the amino acid sequence of SEQ ID NO.52, NO.53, NO.54 or NO.55; or, the complete heavy chain of the humanized monoclonal antibody comprises the amino acid sequence of SEQ ID NO.49, the complete light chain of the humanized monoclonal antibody comprises the amino acid sequence of SEQ ID NO.52, NO.53, NO.54 or NO.55; or, the complete heavy chain of the humanized monoclonal antibody comprises the amino acid sequence of SEQ ID NO.50, the complete light chain of the humanized monoclonal antibody comprises the amino acid sequence of SEQ.ID NO.52 or NO.56.
11. The humanized monoclonal antibody according to claim 7 , wherein the variable region in the heavy chain comprises the amino acid sequence of SEQ ID NO. 6 and the constant region in the heavy chain comprises the amino acid sequence of SEQ ID NO. 41, or the variable region in the light chain comprises the amino acid sequence of SEQ ID NO.14, and the constant region in the light chain comprises the amino acid sequence of SEQ ID NO.43; or, the variable region in the heavy chain comprises an amino acid sequence of SEQ ID NO.23 and the constant region in the heavy chain comprises the amino acid sequence of SEQ ID NO.41, or the variable region in the light chain comprises the amino acid sequence of SEQ ID NO.31 and the constant region in the light chain comprises the amino acid sequence of SEQ ID NO.43; or, the variable region in the heavy chain comprises the amino acid sequence of SEQ ID NO.23 and the constant region in the heavy chain comprises the amino acid sequence of SEQ ID NO.41, or the variable region in the light chain comprises the amino acid sequence of SEQ ID NO.35 and the constant region in the light chain comprises the amino acid sequence of SEQ ID NO.43; or, the variable region in the heavy chain comprises the amino acid sequence of SEQ ID NO.23 and the constant region in the heavy chain comprises the amino acid sequence of SEQ ID NO.41, or the variable region in the light chain comprises the amino acid sequence of SEQ ID NO.33 and the constant region in the light chain comprises the amino acid sequence of SEQ I-D NO.43; or, the variable region in the heavy chain comprises the amino acid sequence of SEQ ID NO.23 and the constant region in the heavy chain comprises the amino acid sequence of SEQ ID NO.41, or the variable region in the light chain comprises the amino acid sequence of SEQ ID NO.37 and the constant region in the light chain comprises the amino acid sequence of SEQ ID NO.43; or, the variable region in the heavy chain comprises the amino acid sequence of SEQ ID NO.27 and the constant region in the heavy chain comprises the amino acid sequence of SEQ ID NO.41, or the variable region in the light chain comprises the amino acid sequence of SEQ ID NO.31 and the constant region in the light chain comprises the amino acid sequence of SEQ ID NO.43; or, the variable region in the heavy chain comprises the amino acid sequence of SEQ ID NO.27 and the constant region in the heavy chain comprises the amino acid sequence of SEQ ID NO.41, or the variable region in the light chain comprises the amino acid sequence of SEQ ID NO.35 and the constant region in the light chain comprises the amino acid sequence of SEQ ID NO.43; or, the variable region in the heavy chain comprises the amino acid sequence of SEQ ID NO.27 and the constant region in the heavy chain comprises the amino acid sequence of SEQ ID NO.41, or the variable region in the light chain comprises the amino acid sequence of SEQ ID NO.33 and the constant region in the light chain comprises the amino acid sequence of SEQ ID NO.43; or, the variable region in the heavy chain comprises the amino acid sequence, of SEQ ID NO.27 and the constant region in the heavy chain comprises the amino acid sequence of SEQ ID NO.41, or the variable region in the light chain comprises the amino acid sequence of SEQ ID NO.37 and the constant region in the light chain comprises the amino acid sequence of SEQ ID NO.43; or, the variable region in the heavy chain comprises the amino acid sequence of SEQ ID NO.25 and the constant region in the heavy chain comprises the amino acid sequence of SEQ ID NO.41, or the variable region in the light chain comprises the amino acid sequence of SEQ ID NO.31 and the constant region in the light chain comprises the amino acid sequence of SEQ ID NO.43; or, the variable region in the heavy chain comprises the amino acid sequence of SEQ ID NO.25 and the constant region in the heavy chain comprises the amino acid sequence of SEQ ID NO.41, or the variable region in the light chain comprises the amino acid sequence of SEQ ID NO.35 and the constant region in the light chain comprises the amino acid sequence of SEQ ID NO.43; or, the variable region in the heavy chain comprises the amino acid sequence of SEQ ID NO.25 and the constant region in the heavy chain comprises the amino acid sequence of SEQ ID NO.41, or the variable region in the light chain comprises the amino acid sequence of SEQ ID NO.33 and the constant region in the light chain comprises the amino acid sequence of SEQ ID NO.43; or, the variable region in the heavy chain comprises the amino acid sequence of SEQ ID NO.25 and the constant region in the heavy chain comprises the amino acid sequence of SEQ ID NO.41, or the variable region in the light chain comprises the amino acid sequence of SEQ ID NO.37 and the constant region in the light chain comprises the amino acid sequence of SEQ ID NO.43; or, the variable region in the heavy chain comprises the amino acid sequence of SEQ ID NO.29 and the constant region in the heavy chain comprises the amino acid sequence of SEQ ID NO.41, or the variable region in the light chain comprises the amino acid sequence of SEQ ID NO.39 and the constant region in the light chain comprises the n amino acid sequence of SEQ ID NO.43; or, the variable region in the heavy chain comprises the amino acid sequence of SEQ ID NO.29 and the constant region in the heavy chain comprises the amino acid sequence of SEQ ID NO.41, or the variable region in the light chain comprises the amino acid sequence of SEQ ID NO.31 and the constant region in the light chain comprises the amino acid sequence of SEQ ID NO.43.
12. A pharmaceutical composition, which comprises the anti-human RANKL monoclonal antibody according to claim 1 .
13. A pharmaceutical composition, which comprises the anti-human RANKL monoclonal antibody according to claim 5 .
14. A pharmaceutical composition, which comprises the anti-human RANKL monoclonal antibody according to claim 6 .
15. A pharmaceutical composition, which comprises the anti-human RANKL monoclonal antibody according to claim 7 .
16. The humanized monoclonal antibody according to claim 6 , wherein the variable region in the heavy chain of the humanized monoclonal antibody is the amino acid sequence of SEQ ID NO.29, and the variable region in the light chain of the humanized monoclonal antibody is selected from amino acid sequences of SEQ ID NO.31 or SEQ ID NO.39.
17. The humanized monoclonal antibody according to claim 16 , wherein a constant region in the heavy chain of the humanized monoclonal antibody is human IgG2, and a constant region in the light chain of the humanized monoclonal antibody is human Kappa; or, a constant region in the heavy chain of the humanized monoclonal antibody has the amino acid sequence of SEQ ID NO.41, and a constant region in the light chain of the humanized monoclonal antibody has the amino acid sequence of SEQ ID NO.43.
18. The humanized monoclonal antibody according to claim 16 , wherein the humanized monoclonal antibody is an antigen binding segment selected from Fab, Fab′ or F(ab′) 2 .
19. The humanized monoclonal antibody according to claim 9 , wherein the complete heavy chain of the humanized monoclonal antibody has the amino acid sequence of SEQ ID NO.50, and the complete light chain of the humanized monoclonal antibody is selected from an amino acid sequence of SEQ ID NO.52 or SEQ ID NO.56.
20. The humanized monoclonal antibody according to claim 11 , wherein the variable region in the heavy chain comprises the amino acid sequence of SEQ ID NO. 29, the constant region in the heavy chain comprises the amino acid sequence of SEQ ID NO.41, the variable region in the light chain comprises the amino acid sequence of SEQ ID NO.39 and the constant region in the light chain comprises the amino acid sequence of SEQ ID NO.43, or the variable region in the heavy chain comprises the amino acid sequence of SEQ ID NO. 29, the constant region in the heavy chain comprises the amino acid sequence of SEQ ID NO. 41, the variable region in the light chain comprises the amino acid sequence of SEQ ID NO.31 and the constant region in the light chain comprises the amino acid sequence of SEQ ID NO.43.
21. A pharmaceutical composition, which comprises the humanized monoclonal antibody of claim 16 .